ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARDX Ardelyx Inc

7.80
-0.26 (-3.23%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ardelyx Inc NASDAQ:ARDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.26 -3.23% 7.80 7.65 11.75 8.11 7.595 8.05 5,051,379 05:00:05

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

01/02/2024 1:00pm

GlobeNewswire Inc.


Ardelyx (NASDAQ:ARDX)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Ardelyx Charts.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2023 financial results and provide a business update.

To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts: Caitlin Lowieclowie@ardelyx.com

1 Year Ardelyx Chart

1 Year Ardelyx Chart

1 Month Ardelyx Chart

1 Month Ardelyx Chart

Your Recent History

Delayed Upgrade Clock